Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 14/20 | 0.82 |
| ▸ | MEN1 | O00255 | 2/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.82 |
| ▸ | USP2 | O75604 | 1/20 | 0.82 |
| ▸ | LMNA | P02545 | 1/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.79 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trandolaprilat SCHEMBL11076552 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA | |
| Trandolaprilat SCHEMBL678354 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA | |
| Trandolaprilat SCHEMBL5567196 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA | |
| Trandolaprilat SCHEMBL9173132 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA | |
| Trandolaprilat SCHEMBL683838 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA | |
| Trandolaprilat SCHEMBL9173121 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA | |
| Trandolaprilat SCHEMBL11286342 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA | |
| Trandolaprilat SCHEMBL5794079 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA | |
| Trandolaprilat SCHEMBL9173113 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA | |
| Trandolaprilat SCHEMBL7388097 | 1.00 | ACE (0.82) | ACEMEN1KMT2AUSP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200276166-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | UNIV CALIFORNIA (US) | 2020-09-03 | — | — | US | disclosed |
| US-10668049-B2 | Methods of treating cognitive decline with transforming growth factor beta inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-06-02 | — | — | US | disclosed |
| US-20160367530-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-12-22 | — | — | US | disclosed |
| US-9468649-B2 | Methods of treating epilepsy with transforming growth factor beta inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-10-18 | — | — | US | disclosed |
| US-20120058949-A1 | Methods of Treating Neurological Disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2012-03-08 | — | — | US | disclosed |
| WO-2010065917-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20060286105-A1 | Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency | LEDBETTER STEVEN | 2006-12-21 | — | — | US | disclosed |
| EP-1620128-A1 | TGF-BETA ANTAGONISTS COMBINED WITH RENIN-ANGIOTENSIN-ALDOSTERON-SYSTEM ANTAGONISTS FOR TREATING RENAL INSUFFICIENCY | GENZYME CORPORATION (US) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004098637-A1 | TGF-BETA ANTAGONISTS COMBINED WITH RENIN-ANGIOTENSIN-ALDOSTERON-SYSTEM ANTAGONISTS FOR TREATING RENAL INSUFFICIENCY | GENZYME CORPORATION (US) | 2004-11-18 | — | — | WO | disclosed |